FDA Grants Accelerated Approval to Dostarlimab-gxly

On April 22, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dostarlimab-gxly for adult patients with mismatch repair deficient recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen.

Read the FDA announcement.

Read the GlaxoSmithKline announcement.

Posted 4/23/2021